1. Home
  2. KURA vs PRDO Comparison

KURA vs PRDO Comparison

Compare KURA & PRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KURA
  • PRDO
  • Stock Information
  • Founded
  • KURA 2014
  • PRDO 1994
  • Country
  • KURA United States
  • PRDO United States
  • Employees
  • KURA N/A
  • PRDO N/A
  • Industry
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • PRDO Other Consumer Services
  • Sector
  • KURA Health Care
  • PRDO Real Estate
  • Exchange
  • KURA Nasdaq
  • PRDO Nasdaq
  • Market Cap
  • KURA 561.9M
  • PRDO N/A
  • IPO Year
  • KURA N/A
  • PRDO N/A
  • Fundamental
  • Price
  • KURA $5.84
  • PRDO $32.57
  • Analyst Decision
  • KURA Strong Buy
  • PRDO Buy
  • Analyst Count
  • KURA 12
  • PRDO 1
  • Target Price
  • KURA $24.50
  • PRDO $40.00
  • AVG Volume (30 Days)
  • KURA 1.3M
  • PRDO 615.3K
  • Earning Date
  • KURA 08-07-2025
  • PRDO 07-30-2025
  • Dividend Yield
  • KURA N/A
  • PRDO 1.59%
  • EPS Growth
  • KURA N/A
  • PRDO N/A
  • EPS
  • KURA N/A
  • PRDO 2.25
  • Revenue
  • KURA $67,991,000.00
  • PRDO $726,003,000.00
  • Revenue This Year
  • KURA $109.86
  • PRDO $24.62
  • Revenue Next Year
  • KURA $107.90
  • PRDO $3.83
  • P/E Ratio
  • KURA N/A
  • PRDO $14.54
  • Revenue Growth
  • KURA N/A
  • PRDO 6.35
  • 52 Week Low
  • KURA $5.41
  • PRDO $20.32
  • 52 Week High
  • KURA $23.48
  • PRDO $34.60
  • Technical
  • Relative Strength Index (RSI)
  • KURA 39.08
  • PRDO 55.44
  • Support Level
  • KURA $5.73
  • PRDO $31.70
  • Resistance Level
  • KURA $6.01
  • PRDO $33.44
  • Average True Range (ATR)
  • KURA 0.30
  • PRDO 0.83
  • MACD
  • KURA -0.09
  • PRDO -0.17
  • Stochastic Oscillator
  • KURA 3.68
  • PRDO 49.80

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Share on Social Networks: